HC Wainwright Has Bearish Forecast for Immunic Q3 Earnings

Key Points

• HC Wainwright analysts have reduced their Q3 2025 earnings per share estimate for Immunic from ($0.18) to ($0.20), while maintaining a "Buy" rating and a price objective of $10.00.
• Immunic recently reported a quarterly EPS of ($0.20), missing analysts' expectations by ($0.02), with a consensus estimate for the current full-year earnings at ($0.94) per share.
• Despite the reduced earnings estimates, analysts maintain a positive outlook with one sell rating, five buy ratings, and a consensus target price set at $7.50.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Analysts at HC Wainwright reduced their Q3 2025 EPS estimates for Immunic in a research report issued to clients and investors on Tuesday, August 12th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.20) for the quarter, down from their prior forecast of ($0.18). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunic's Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($1.01) EPS, FY2027 earnings at ($0.82) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at ($0.17) EPS.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02).

A number of other research firms have also weighed in on IMUX. B. Riley reissued a "buy" rating and set a $5.00 price objective (down previously from $6.00) on shares of Immunic in a research note on Friday, May 23rd. William Blair reissued an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. Finally, D. Boral Capital reissued a "buy" rating and set a $10.00 price objective on shares of Immunic in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $7.50.

Immunic Trading Down 8.6%

Shares of NASDAQ:IMUX traded down $0.0845 during trading on Thursday, reaching $0.8940. 948,582 shares of the company traded hands, compared to its average volume of 1,239,342. The firm has a market capitalization of $88.19 million, a price-to-earnings ratio of -0.73 and a beta of 1.39. Immunic has a 52-week low of $0.56 and a 52-week high of $2.11. The business's fifty day moving average is $0.86 and its 200-day moving average is $0.97.

Hedge Funds Weigh In On Immunic

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. purchased a new position in Immunic during the fourth quarter valued at $37,000. Barclays PLC purchased a new position in Immunic during the fourth quarter valued at $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Immunic by 90.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after buying an additional 96,894 shares during the period. Bridgeway Capital Management LLC lifted its position in Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after buying an additional 22,200 shares during the period. Finally, Jane Street Group LLC lifted its position in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after buying an additional 152,726 shares during the period. Hedge funds and other institutional investors own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.